Maia Biotechnology

Maia Biotechnology ROA

The Return on Assets (ROA) of Maia Biotechnology (MAIA) as of Nov 10, 2026 is -230.78 %. In the previous year, Return on Assets (ROA) was -228.99 % — a change of 0.78% (lower).

ROA

-230.78 %

YoY

0.78%

Last updated:

In 2025, Maia Biotechnology's return on assets (ROA) was -230.78 %, a 0.78% increase from the -228.99 % ROA in the previous year.

The Maia Biotechnology ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-374.33 USD
Jan 1, 2020
-889.03 USD
Jan 1, 2021
-110.39 USD
Jan 1, 2022
-131.17 USD
Jan 1, 2023
-261.31 USD
Jan 1, 2024
-228.99 USD
Jan 1, 2025
-230.78 USD
The Maia Biotechnology ROA history
YEARROAYoY
-230.78 %+0.78%
-228.99 %-12.37%
-261.31 %+99.21%
-131.17 %+18.83%
-110.39 %-87.58%
-889.03 %+137.50%
-374.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Maia Biotechnology Stock analysis

What does Maia Biotechnology do? MAIA Biotechnology, Inc. generates revenue through the development and commercialization of oncology drug candidates, focusing on targeted immuno-oncology therapies for difficult-to-treat cancers. The company's pipeline includes THIO (6-thio-dG, 6-thio-2’-deoxyguanosine), a telomere-targeting agent in Phase II clinical development for Non-Small Cell Lung Cancer, and Libtayo for advanced non-small-cell lung cancer treatment. MAIA is advancing a second-generation program with five compounds designed to improve specificity towards cancer cells and increase anticancer activity. The firm targets pharmaceutical companies and healthcare providers seeking innovative cancer treatments. The company's primary products are THIO and Libtayo, with THIO being a potentially first-in-class small molecule. MAIA is developing these therapies to improve and extend the lives of cancer patients, focusing on non-small-cell lung cancer and other difficult-to-treat cancers. The firm's second-generation pipeline aims to discover new compounds with enhanced properties compared to existing therapies. MAIA's clinical-stage approach allows it to partner with pharmaceutical entities for development and commercialization. MAIA Biotechnology's revenue model relies on the progression of its clinical-stage therapies through development phases, with potential partnerships and licensing agreements for commercialization. The company's focus on telomere-targeting agents like THIO positions it in the oncology drug development market. MAIA's pipeline includes Phase II studies for THIO in Non-Small Cell Lung Cancer, indicating near-term potential for partnerships or sales. The firm targets healthcare providers and pharmaceutical companies as key segments for its therapies. Maia Biotechnology is one of the most popular companies on Eulerpool.

ROA Details

Understanding Maia Biotechnology's Return on Assets (ROA)

Maia Biotechnology's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Maia Biotechnology's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Maia Biotechnology's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Maia Biotechnology’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Maia Biotechnology stock

Return on Assets (ROA) of Maia Biotechnology is -230.78 % in 2025.

Return on Assets (ROA) of Maia Biotechnology changed from -228.99 % to -230.78 %, representing a 0.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Maia Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Maia Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Maia Biotechnology

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Maia Biotechnology